Nomura has upgraded Sun Pharma to a buy call with a target price of ₹1,960 per share, implying a potential upside of around 16% from the current market price of ₹1,686. The brokerage said the moderation in expectations around the specialty segment, coupled with robust growth in branded generics, has made the stock’s risk-reward profile favourable.
It added that Q2FY26 EBITDA performance was in line with estimates, supported by steady operational execution. Nomura highlighted that Sun Pharma’s valuations remain well-supported by strong domestic growth, a diversified business presence across markets, and a healthy balance sheet.
At the time of the report, Sun Pharma shares were trading at ₹1,686 on the exchange.
Disclaimer: The views and target price mentioned are those of the brokerage firm (Nomura). This article is based solely on the provided inputs and is intended for informational purposes only. No investment advice.
